Co-Diagnostics and ReadyGo Partner to Expand Blood-Based Ebola Testing — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Co-Diagnostics and ReadyGo Diagnostics are collaborating to evaluate blood-based molecular testing at the point of need, starting with Ebola detection.
The collaboration combines ReadyGo's GoCollect® sample-preparation technology with Co-Dx's PCR platform.
Feasibility work has begun to assess compatibility and workflow integration of the two technologies.
The ongoing Ebola outbreak in the Democratic Republic of the Congo has reported 6,757 confirmed cases and 3,267 deaths as of September 7, 2026.
Success could expand the Co-Dx PCR platform to include testing for HIV and hepatitis B and C.

The big picture

The collaboration aims to address the critical need for rapid, decentralized molecular testing in resource-limited settings, particularly during fast-moving outbreaks like Ebola. Success could significantly expand the Co-Dx PCR platform's capabilities, tapping into larger diagnostic markets for bloodborne pathogens. The partnership aligns with broader trends in point-of-care diagnostics and global health response strategies.

What we're watching

Technical Feasibility: Whether the integration of GoCollect® and Co-Dx PCR technologies will prove compatible and effective for blood-based testing.
Regulatory Pathway: The pace at which the combined technologies can navigate regulatory approvals for decentralized Ebola detection and other applications.
Market Expansion: How successful blood-based testing could broaden the Co-Dx PCR platform's addressable market, including HIV and hepatitis testing.